Table 1.
Baseline characteristics of SOTRs. 1 tacrolimus; 2 everolimus; 3 p-value of [A], [B], and [C] from all patients was not significant (p-value between A and B = 0.253, between A and C = 0.303, and between B and C = 0.962). Welch’s t-test was used for statistical analyses, and p < 0.05 was considered statistically significant. Abbreviations: yr, year; SD, standard deviation; M, male; n, number; MMF, mycophenolate mofetil.
| Variable | TxVac (n = 15) |
TxRec (n = 10) |
p-Value |
|---|---|---|---|
| Age, mean yr (SD) | 58 (13) | 51 (14) | 0.2370 |
| Gender, M (%) | 9 (60) | 7 (70) | |
| Type of transplant, n (%) | |||
| Kidney | 3 (20) | 2 (20) | |
| Lung | 6 (40) | 4 (40) | |
| Liver | 4 (26.7) | 3 (30) | |
| Heart | 2 (13.3) | 1 (10) | |
| Time from transplant, median yr (range) | 6 (2–15) | 10.5 (2–28) | 0.0846 |
| Immunosuppressive treatment, n (%), | |||
| Calcineurin inhibitors 1 (3.2 to 14.0 ng/mL) mean ng/mL (SD) | 14 (93.3%), 7.06 (2.59) |
9 (90%), 7.26 (3.83) |
|
| mTOR inhibitors 2 (3.39 to 5.0 ng/mL) mean ng/mL (SD) | 2 (13.3%), 4.20 (1.15) |
------ | |
| Mycophenolate-mofetil (MMF) (360 to 2000 mg) mean mg (SD) | 9 (60%), 826.66 (284.07) |
8 (80%), 1125 (353.5) |
|
| Steroids (5 to 14.64 mg) mean mg (SD) | 8 (53.3%), 6.49 (3.53) |
5 (50%), 6 (2.24) |
|
| Timespan between 3° dose and 4° dose, mean days (range) | 168.33 (116–246) | ------ | |
| Timespan between 3° dose and COVID-19, mean days (range) | ------ | 134.50 (64–221) | |
| Timespan between 3° dose/sampling, mean days (range) [A] | 52.27 (21–110) 3 | 54.1 (19–98) | 0.8655 |
| Timespan between 4° dose/sampling, mean days (range) [B] | 65.33 (26–127) 3 | ------ | |
| Timespan between COVID-19/sampling, mean days (range) [C] | ------ | 64.70 (28–141) 3 | |
| Comorbidities, n (%) | |||
| Diabetes | 5 (33.3) | 3 (30) | |
| Obesity | 1 (6.67) | 2 (20) | |
| Hypertension | 4 (26.7) | 5 (50) | |
| Dyslipidaemia | 3 (20) | 2 (20) | |
| Active or previous smoker | 4 (26.7) | 2 (20) | |
| Cardiovascular disease | 3 (20) | 4 (40) | |
| Kidney disease | 1 (6.67) | 3 (30) | |
| Pulmonary disease | 2 (13.3) | 0 | |
| Gastrointestinal disease | 5 (33.3) | 2 (20) | |
| Endocrinal disease | 4 (26.7) | 0 | |
| History of malignancy | 6 (40) | 2 (20) |